doi: 10.1161/01.STR.0000027274.03779.F3
(Stroke. 2002;33:2297.)
© 2002 American Heart Association, Inc.
Original Contributions |
Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT1 Antagonist
From the Section on Pharmacology, Intramural Research Program, National Institute of Mental Health, Bethesda, Md.
Correspondence to Juan M. Saavedra, MD, Section on Pharmacology, Intramural Research Program, National Institute of Mental Health, 10 Center Dr, Bldg 10, Room 2D-57, Bethesda, MD 20892. E-mail Saavedrj{at}irp.nimh.nih.gov
Background and Purpose— Pretreatment with angiotensin II AT1 receptor antagonists protects against cerebral ischemia. We studied whether modulation of cerebral blood flow (CBF) and morphometric changes in brain arteries participated in this protective mechanism.
Methods— We pretreated adult spontaneously hypertensive rats with equally antihypertensive doses of candesartan (0.1 or 0.3 mg/kg per day), nicardipine (0.1 mg/kg per day), or captopril (3.0 mg/kg per day) for 3 or 28 days via subcutaneous osmotic minipumps followed by permanent left middle cerebral artery (MCA) occlusion distal to the origin of the lenticulostriate arteries. We measured CBF by autoradiography with 4-iodo-[N-methyl-14C]antipyrine 3 hours after operation and the areas of infarct and tissue swelling 24 hours after operation. Morphometric changes in the MCA were studied after antihypertensive treatment.
Results— Twenty-eight days of candesartan pretreatment decreased the infarct area by 31%; reduced the CBF decrease at the peripheral area of ischemia and the cortical volume of severe ischemic lesion, where CBF was <0.50 mL/g per minute; increased the MCA external diameter by 16%; and reduced the media thickness of the MCA by 23%. Captopril pretreatment for 28 days decreased the infarct area by 25%. Pretreatment with candesartan for 3 days or nicardipine for 28 days was ineffective.
Conclusions— Angiotensin II system inhibition protects against neuronal injury more effectively than calcium channel blockade. Protection after AT1 receptor blockade is not directly correlated with blood pressure reduction but with normalization of MCA media thickness, leading to increased arterial compliance and reduced CBF decrease during ischemia at the periphery of the lesion.
Key Words: cerebral blood flow • hypertension • peptides • receptors • stroke
This article has been cited by other articles:
 |
|
 |
|
  A. P. Mecca, T. E. O'Connor, M. J. Katovich, and C. Sumners Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion Exp Physiol, August 1, 2009; 94(8): 937 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. McCarthy, A. Vinh, J. K. Callaway, and R. E. Widdop Response to Letter by Tsuda Stroke, July 1, 2009; 40(7): e494 - e494. [Full Text] [PDF]
|
|
|
|
|
|
C. A. McCarthy, A. Vinh, J. K. Callaway, and R. E. Widdop Angiotensin AT2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke * Supplemental Materials and Methods Stroke, April 1, 2009; 40(4): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Inaba, M. Iwai, Y. Tomono, I. Senba, M. Furuno, H. Kanno, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes Stroke, February 1, 2009; 40(2): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kozak, A. Kozak, M. H. Johnson, H. F. Elewa, and S. C. Fagan Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 773 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ishikawa, E. Sekizuka, N. Yamaguchi, H. Nakadate, S. Terao, D. N. Granger, and H. Minamitani Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral microvasculature Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2306 - H2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, J. Pavel, M. Macova, Z.-X. Yu, H. Imboden, L. Ge, T. Nishioku, J. Dou, E. Delgiacco, and J. M. Saavedra AT1 Receptor Blockade Regulates the Local Angiotensin II System in Cerebral Microvessels From Spontaneously Hypertensive Rats Stroke, May 1, 2006; 37(5): 1271 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Munzenmaier and A. S. Greene Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H512 - H516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Vincent, Y. W. Kwan, S. Lung Chan, C. Perrin-Sarrado, J. Atkinson, and J.-M. Chillon Constrictor and Dilator Effects of Angiotensin II on Cerebral Arterioles Stroke, December 1, 2005; 36(12): 2691 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kario, J. Ishikawa, S. Hoshide, Y. Matsui, M. Morinari, K. Eguchi, S. Ishikawa, and K. Shimada Diabetic Brain Damage in Hypertension: Role of Renin-Angiotensin System Hypertension, May 1, 2005; 45(5): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shah Role of the renin-angiotensin system in the pathogenesis of preeclampsia Am J Physiol Renal Physiol, April 1, 2005; 288(4): F614 - F625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Forder, D. H. Munzenmaier, and A. S. Greene Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Papademetriou, C. Farsang, D. Elmfeldt, A. Hofman, H. Lithell, B. Olofsson, I. Skoog, P. Trenkwalder, A. Zanchetti, and for the SCOPE Study Group Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE) J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1175 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke Neurology, July 27, 2004; 63(2): 208 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ando, J. Zhou, M. Macova, H. Imboden, and J. M. Saavedra Angiotensin II AT1 Receptor Blockade Reverses Pathological Hypertrophy and Inflammation in Brain Microvessels of Spontaneously Hypertensive Rats Stroke, July 1, 2004; 35(7): 1726 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kusaka, G. Kusaka, C. Zhou, M. Ishikawa, A. Nanda, D. N. Granger, J. H. Zhang, and J. Tang Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2442 - H2451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Delles, G. Michelson, J. Harazny, S. Oehmer, K. F. Hilgers, and R. E. Schmieder Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients Stroke, June 1, 2004; 35(6): 1289 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bregonzio, I. Armando, H. Ando, M. Jezova, G. Baiardi, and J. M. Saavedra Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G414 - G423. [Abstract] [Full Text] [PDF]
|
|